Novel Treatments for
Attention-Deficit/Hyperactivity Disorder in Children and Adults
Volume 04
Suppl 04

Articles   [top]

3  Overview and Neurobiology of Attention Deficit/Hyperactivity Disorder

[Full Text]

10  Major Life Activity and Health Outcomes Associated with Attention Deficit/Hyperactivity Disorder

[Full Text]

16  Novel Treatments for Attention Deficit/Hyperactivity Disorder in Children

[Full Text]

23  Adaptive Change Related to Medication Treatment of ADHD: Listening to Parents of Children in Clinical Trials of a Novel Nonstimulant Medication

[Full Text]

29  Management of ADHD in Adults

[Full Text]

36  Psychosocial Treatments for Attention Deficit/Hyperactivity Disorder in Children

[Full Text]

44  Drug Development Process for a Product with a Primary Pediatric Indication

[Full Text]

50  Safety Profile of Atomoxetine in the Treatment of Adolescents and Children with ADHD

[Full Text]

information for authors



Editor’s Choice

Few areas of primary care psychiatry are more fraught with confusion and controversy than attention-deficit/hyperactivity disorder (ADHD). ADHD is variably considered a true medical illness, an extension of the world of learning disabilities, or an overrecognized and overtreated "pop" diagnosis of modern living. One thing is certain—primary care physicians among all providers are most likely to encounter ADHD. Specific training in the recognition, assessment, and treatment of ADHD is sorely lacking in primary care postgraduate programs. More current information on diagnosis, comorbidity, and management is slow to disseminate into our care settings.

The Primary Care Companion to The Journal of Clinical Psychiatry is pleased to offer our readers this supplement containing a series of articles focusing on ADHD neurobiology, diagnosis (including information for adult patients), treatment (medical, psychosocial, pediatric, and adult), and the association of ADHD with major life events. Importantly, the supplement includes information on atomoxetine, a selective norepinephrine reuptake inhibitor soon to be available for clinical use. Atomoxetine is the first nonstimulant medication to receive an approvable letter from the U.S. Food and Drug Administration for the treatment of ADHD. A commentary on ADHD in primary care settings concludes the supplement.

We hope that this information is of practical use for our readers. Your comments are appreciated.

J. Sloan Manning, M.D.

Editor in Chief

The Primary Care Companion to the Journal of Clinical Psychiatry